Literature DB >> 7558714

In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells.

D L Budenz1, J Bennett, L Alonso, A Maguire.   

Abstract

PURPOSE: To determine whether a reporter gene can be introduced into adult mammalian corneal endothelial and trabecular meshwork cells in vivo using a recombinant replication-deficient adenovirus.
METHODS: Purified replication-deficient adenovirus containing the cytomegalovirus-promoted Escherichia coli reporter gene, lacZ, was injected into the vitreous cavities or anterior chambers of 30 adult CD-1 mice using the contralateral eyes as controls. LacZ expression was assessed histochemically in enucleated eyes from 2 to 21 days after injection using the beta-Galactosidase (beta-Gal) assay.
RESULTS: LacZ expression was demonstrated in corneal endothelial and trabecular meshwork cells for as long as 14 days after injection. beta-Gal activity was also observed in lens and iris epithelial cells. There was no toxicity of the adenoviral vector demonstrated histologically, and no nonocular tissues expressed lacZ as measured by beta-Gal assay.
CONCLUSIONS: A functional gene can be transferred in vivo into adult mammalian corneal endothelial and trabecular meshwork cells using a replication-defective adenoviral vector. Gene expression is relatively short-lived compared to that demonstrated previously in other ocular tissues (photoreceptors and retinal pigment epithelium). Adenoviral vectors may be a viable means for short-term delivery of therapeutic genes in vivo to cells in the anterior segment of the eye.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558714

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  25 in total

1.  Lentiviral mediated gene delivery to the anterior chamber of rodent eyes.

Authors:  Pratap Challa; Coralia Luna; Paloma B Liton; Beth Chamblin; John Wakefield; Ram Ramabhadran; David L Epstein; Pedro Gonzalez
Journal:  Mol Vis       Date:  2005-06-21       Impact factor: 2.367

2.  Novel AAV serotypes for improved ocular gene transfer.

Authors:  Corinna Lebherz; Albert Maguire; Waixing Tang; Jean Bennett; James M Wilson
Journal:  J Gene Med       Date:  2008-04       Impact factor: 4.565

3.  Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.

Authors:  LaKisha K Buie; Carol A Rasmussen; Eric C Porterfield; Vinod S Ramgolam; Vivian W Choi; Silva Markovic-Plese; Richard J Samulski; Paul L Kaufman; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-13       Impact factor: 4.799

Review 4.  Gene therapy for inherited retinal degeneration.

Authors:  R R Ali; M B Reichel; D M Hunt; S S Bhattacharya
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

5.  Outflow tract ablation using a conditionally cytotoxic feline immunodeficiency viral vector.

Authors:  Ze Zhang; Amardeep S Dhaliwal; Harry Tseng; James D Kim; Joel S Schuman; Robert N Weinreb; Nils A Loewen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

Review 6.  Corneal gene therapy: basic science and translational perspective.

Authors:  Rajiv R Mohan; Jason T Rodier; Ajay Sharma
Journal:  Ocul Surf       Date:  2013-02-13       Impact factor: 5.033

Review 7.  Prospects for genetic intervention in primary open-angle glaucoma.

Authors:  M K Wirtz; T S Acott; J R Samples; J C Morrison
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 8.  Gene transfer to the outflow tract.

Authors:  Yalong Dang; Ralitsa Loewen; Hardik A Parikh; Pritha Roy; Nils A Loewen
Journal:  Exp Eye Res       Date:  2016-04-27       Impact factor: 3.467

9.  Optimizing gene transfer to conventional outflow cells in living mouse eyes.

Authors:  G Li; P Gonzalez; L J Camras; I Navarro; J Qiu; P Challa; W D Stamer
Journal:  Exp Eye Res       Date:  2013-01-18       Impact factor: 3.467

Review 10.  Gene therapy targeting glaucoma: where are we?

Authors:  Xuyang Liu; Carol A Rasmussen; B'ann T Gabelt; Curtis R Brandt; Paul L Kaufman
Journal:  Surv Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.